Table 3 Regression analysis for the outcomes after PS matching
Outcomes | Early | Late | P-value | Hazard ratio (95%CI) | P-value$ |
|---|---|---|---|---|---|
30-day mortality, n (%) | 22 (23.2) | 25 (26.6) | 0.5846^^ | 2.54 (1.24, 5.22) | 0.01 |
Odds ratio (95%CI) | P-value$* | ||||
Developing of vancomycin resistance organism (s) (e.g. (VRSA, VISA), n (%) | 3 (2.9) | 3 (2.9) | 0.9905** | 4.28 (0.47, 38.8) | 0.19 |
Eradication of microorganism within 4–5 days of vancomycin initiation, n (%) | 72 (69.2) | 70 (66.7) | 0.6913^^ | 1.49 (0.75, 2.96) | 0.25 |
Vancomycin induced acute kidney injury, n (%) | 13 (12.5) | 19 (18.1) | 0.2614^^ | 2.59 (1.01, 6.65) | 0.04 |
Beta coefficient (Estimates) (95%CI) | P-value $** | ||||
ICU length of stay (Days), Median (Q1, Q3) & | 15.0 (9.00, 27.00) | 13.0 (4.00, 24.00) | 0.1802^ | − 0.27 (− 0.58, 0.05) | 0.10 |
Hospital length of stay (Days), Median (Q1, Q3) & | 26.0 (14.00, 42.00) | 24.0 (15.00, 44.00) | 0.8722^ | 0.10 (− 0.22, 0.43) | 0.54 |